<DOC>
	<DOCNO>NCT00537511</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose safety CC-4047 ( pomalidomide ) give combination cisplatin etoposide patient extensive disease small cell lung cancer .</brief_summary>
	<brief_title>A Phase I/II Study Determine Maximum Tolerated Dose ( MTD ) Safety CC-4047 ( Pomalidomide ) Administered Conjunction With Cisplatin Etoposide</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>signature inform consent Age &gt; = 18 histologically cytologically confirm small cell lung cancer ( SCLC ) extensive stage SCLC Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 brain metastasis asymptomatic require steroid control females child bear potential must use two form birth control pregnant lactating female prior use cytotoxic chemotherapy surgery within 14 day study radiation within 14 day study prior therapy CC4047 ( pomalidomide ) , lenalidomide thalidomide concurrent use anticipate use anticancer agent absolute neutrophil count ( ANC ) &lt; 1500/mm^3 platelet &lt; 100 x 10^3/ÂµL serum creatinine &gt; 2.5 mg/dL serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) &gt; 3.0 x upper limit normal ( ULN ) serum total bilirubin &gt; 1.8 mg/dL uncontrolled hypercalcemia creatinine clearance &lt; 50 mL/min uncontrolled hypertension neuropathy &gt; = grade 2 body mass index ( BMI ) &gt; = 40 active invasive malignancy require treatment know chronic infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) inability unwillingness comply birth control requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>